Quick ReadPlain-language overview · read this first
Agilent is a global laboratory instruments and services platform, at a current price of $113.78 and a P/E of 25.1x, rated Watch.
FY2025 revenue was $6.948 billion, non-instrument $4.521 billion, and the CrossLab operating margin 32.5%; the installed base of 285,000 laboratories + 750,000 instruments is the real cash cow. The moat rests on brand, switching costs, and the service network, with no reliance on a single patent. Five-year cumulative net income of $6.296 billion matches FCF of $6.317 billion, with net debt/EBITDA <1x. The counterexample: the CEO/CFO changed in succession in 2024-2025, and the combined $1.865 billion of BIOVECTRA + Biocare acquisitions is unvalidated, so capital allocation remains to be proven.
Three-tier anchors of $55-65/80-95/120-135, ideal buy $70-85; if growth falls short of expectations combined with multiple mean reversion, $55-75 corresponds to a permanent drawdown of 35%-50%. A good company, but not a good price—wait for a better entry point.
LeadA high-quality laboratory tools and services company whose CrossLab services/consumables franchise is highly sticky, with solid cash flow and low debt. At the current $113.78, mid-single-digit growth is already fully priced in and the margin of safety is insufficient; rating Watch, with an ideal buy zone of $70-85.
Prices in the article are as of publication; see the valuation band above for the live price.
Conclusion First
This report bases its judgment primarily on Agilent's latest public materials: the FY2025 annual report and 10-K, the 10-Q through January 31, 2026, the 2026 proxy statement, the 2024 analyst day materials, and market data around the close on May 20, 2026. The current share price is about $113.78, market capitalization about $32.3 billion, and the trailing-twelve-month GAAP P/E about 25.1x. The company posted FY2025 revenue of $6.948 billion and Q1 FY2026 revenue of $1.798 billion, and it maintains FY2026 revenue guidance of $7.3 billion to $7.5 billion.
| Item | Judgment |
|---|---|
| Investment Rating | Watch |
| Core Judgment | This is a high-quality laboratory tools and services company that I can understand and would be willing to track for the long term, but at the current price it does not offer a sufficient margin of safety. The most valuable part is actually the high-margin, high-stickiness CrossLab services/consumables/software platform, rather than the more cyclical instrument sales themselves. The company's cash generation is real, its balance sheet is solid, and governance is generally sound, but M&A activity has increased over the past two years and turnover in the CEO and CFO roles has raised execution uncertainty. The current price looks more like paying a reasonable-to-slightly-expensive price for a "good company" than acquiring a business at a "good price." |
| Does the current price offer a margin of safety | Not obvious |
| Suitable investor type | Long-term value investors who weight quality heavily and can patiently wait for the right price; less suitable for short-term growth investors who only look at a "cheap P/E" or chase high volatility |
| Biggest uncertainty | The cyclicality of the instrument business outside CrossLab; M&A integration and capital allocation; the current valuation already prices in mid-single-digit growth fairly fully |
My preliminary conclusion: If I view Agilent as a business to be held for more than 10 years, it broadly meets the requirements of "understandable, good business, decent cash flow, low debt"; but it has not reached the state of "clearly undervalued, should be bought aggressively today." For more conservative long-term capital, the most reasonable action is not to chase the price but to place it on a high-quality watch list and wait for a better entry point.
The Business, the Industry, and the Moat
How exactly does this company make money? At its core, Agilent supplies analytical instruments, software, services, consumables, and application support to laboratories worldwide, serving the life sciences, diagnostics, pharmaceutical, food, environmental, forensic, chemical, and advanced-materials markets. On an FY2025 basis, the company is organized into three business segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. FY2025 revenue for the three segments was $2.726 billion, $2.908 billion, and $1.314 billion respectively; by revenue type, instrument revenue was $2.427 billion and non-instrument revenue was $4.521 billion, showing that the company no longer relies solely on one-time equipment sales but instead depends to a considerable degree on services, consumables, reagents, software, repair, compliance, and laboratory support.
Who are the customers, and is the revenue recurring? The largest FY2025 end market was Pharma & Biopharma ($2.507 billion), followed by Chemicals & Advanced Materials ($1.561 billion) and Diagnostics & Clinical ($1.029 billion). Academia & Government was only $540 million, less than a tenth of FY2025 revenue, so U.S. research-budget fluctuations have an impact but are not a fatal single point. The company discloses that no single customer accounts for more than 10% of revenue, and no single customer accounts for more than 10% of accounts receivable, indicating good customer diversification.
Cost structure and predictability. From a long-term business owner's perspective, what matters most about Agilent is this: its most profitable activity is not "selling an instrument" but the services, consumables, software, and compliance revenue it continuously collects around a vast installed base. The company's 2024 analyst day explicitly emphasized that it supports 285,000 laboratories, covers 750,000+ instruments, raised service-contract attach rates by about 400 basis points over FY2020-2024, and that over the past decade non-instrument businesses contributed 80% of the company's revenue growth. This means its business model is migrating from an "equipment cycle" toward "monetizing the installed base."
What stage is the industry in? This is not a declining industry; it is a maturing, mid-speed growth industry. Management's judgment at the 2024 analyst day was that the underlying markets served by LDG and ACG grow roughly 4%-6% over the long run, and the company's overall long-term growth algorithm is about 5%-7%; Applied Markets grows more slowly, but subsegments such as food safety, PFAS, semiconductors, and batteries grow faster. Demand is fundamentally driven by pharmaceutical R&D, quality control, regulatory upgrades, and laboratory-efficiency gains; long-term demand is relatively stable, but capital expenditure and regional cycles create periodic swings.
Competitive landscape. In its 10-K, Agilent itself lists its main competitors, including Thermo Fisher, Danaher's AB Sciex and Leica, Roche Ventana, Shimadzu, Waters, and Bruker. The company explicitly acknowledges that these markets feature "rapidly evolving industry standards and intense competition," with competition spanning product performance, reliability, application capability, quality of support, global channel coverage, and price. This shows it is not a monopoly business, nor a network-effect platform, but a high-end tools company that wins through its technology and service system.
How to assess the moat. 【Fact】Agilent's patents are not its main moat; the company even states directly in its 10-K that no single patent, license, or intellectual property right is in itself material or irreplaceable. This matters, because it tells us that this company relies not on "some exclusive patent" but on brand reputation, validated performance, installed base, service system, regulatory-compliance experience, and customer switching costs.
【Inference】Agilent's strongest moat is concentrated in CrossLab. Because once a laboratory purchases a piece of equipment, the subsequent maintenance, calibration, compliance, consumables matching, software interfaces, and workflow training naturally lock the customer into the original manufacturer or a high-trust third-party system. In FY2025, CrossLab revenue was $2.908 billion with a segment operating margin of 32.5%, markedly higher than the other two segments; in Q1 FY2026, CrossLab's operating margin was still 31.6%. This kind of high margin resembles an "installed-base service platform" rather than a one-time equipment-selling business.
【Opinion】My moat conclusion is: it has brand and reputation, it has switching costs, it has a channel and service network, it has some economies of scale, and the regulatory barriers are stronger in the diagnostics/pathology business, but network effects are weak, pure cost advantages are limited, and the patent moat is not deep. This is a moderately strong but not unassailable moat. It currently looks stable to slightly widening, especially in CrossLab, pathology diagnostics, specialty CDMO, and software/automation; but the instrument hardware itself remains exposed to technological competition and cyclical swings. Replicating this system cannot be done in two or three years by throwing money at it, particularly the global service network, the team of application specialists, and the validated installed-base relationships.
Pricing power and cyclical resilience. In 2024, 2025, and Q1 2026, the company repeatedly mentioned targeted pricing increases, indicating that Agilent has some ability to raise prices in an environment of inflation, tariffs, and rising wages. At the same time, even though revenue declined year over year in 2024 and 2023 bore pressure from China and pharma capex, the company still maintained an operating margin near 20%-23% and net income above $1 billion, proving that this is not a fragile model that swings to a loss the moment conditions worsen.
Overall scoring. Business understandability 4/5; industry attractiveness 4/5; moat strength 4/5. If the exchange closed for 5 years, I would be willing to continue holding this business; but only on the condition that the purchase price does not pre-consume the next decade's benefits in advance.
Management and Capital Allocation
Is management trustworthy? Agilent completed a CEO transition in 2024, with Padraig McDonnell formally taking over as CEO in May 2024; in July 2025 the former CFO Robert McMahon resigned, and Adam Elinoff became CFO in November 2025. This means the management team is in a "new CEO + new CFO" break-in phase, and any assessment should be more conservative than for a stable, decade-long veteran team.
Governance is generally strong. The 2026 proxy statement shows that 10 of the board's 11 directors are independent, and the company is moving, with shareholder support, to gradually eliminate the classified board; it also discloses arrangements prohibiting executives and directors from hedging, short selling, or pledging stock, and it maintains relatively strict stock-ownership guidelines. The 2025 Say-on-Pay shareholder support rate was 89%. These are all more characteristic of a mature, large, high-quality U.S. company than a loosely governed story stock.
But interest alignment is not especially strong. The 2026 proxy statement shows that directors and executives together still own less than 1% of the stock; Padraig McDonnell's beneficial ownership as of January 21, 2026 totaled about 54,582 shares, worth several million dollars at the current price—real alignment, but far from "management holding a heavy stake and breathing the same air as shareholders." This lowers my confidence in "exceptional ultra-long-term capital-allocation talent."
The capital-allocation record is mixed. 【Fact】The company has paid dividends consistently over the long term, with cash dividends of $265 million, $274 million, and $282 million in FY2023, FY2024, and FY2025 respectively; it has also repurchased shares consistently, spending roughly $575 million, $1.150 billion, and $425 million in cash on buybacks in FY2023, FY2024, and FY2025, and in 2024 the board approved a new $2 billion repurchase program.
【Inference】These buybacks are not entirely the classic value-investing move of "repurchasing aggressively when undervalued." The company states clearly in its filings that one important goal of the 2024 repurchase program is to reduce or eliminate the dilution from employee equity incentives. This means a substantial portion of the buybacks carries an "anti-dilution" character rather than pure value creation. Even so, the share count fell from about 306.2 million shares at the end of 2020 to about 282.7 million shares in Q1 FY2026, a cumulative reduction of nearly 7.7%, so shareholders have not been severely diluted.
Its M&A record warrants more caution. In 2024 the company acquired BIOVECTRA for $915 million in cash, strengthening its CDMO capability; in March 2026 it announced it would acquire Biocare Medical for $950 million in cash, doubling down on pathology diagnostics. Both moves are directionally focused on high-growth, high-stickiness areas, so the logic is not disorderly. The problem is that Agilent is not a path relying entirely on organic growth; it increasingly depends on "M&A + platform integration" to drive structural upgrades. At the same time, in 2023 the company also exited Resolution Bioscience and took a large impairment. In other words: its acquisitions are not reckless, but they are certainly not "spot-on every time."
My judgment on management and capital allocation. 【Opinion】I believe Agilent's management is generally honest, professional, and long-term-oriented, with a governance framework above average; but by the standard of "Buffett-style capital allocation," it has not yet proven itself to be the kind of top allocator that can consistently deploy every dollar of capital at excess returns with extremely high certainty. My score is 3.5/5. If BIOVECTRA and Biocare integrate well over the next two to three years, CrossLab keeps expanding, and buybacks become more restrained and more valuation-aware, the score can be revised up; conversely, if another large strategic impairment appears, this item will deteriorate markedly.
Financial Quality and Owner Earnings
First, the most important financial outline. The table below shows the FY2021-FY2025 core metrics I compiled from the company's historical 10-Ks; FCF uses the most conservative definition, namely operating cash flow minus capital expenditures.
| Fiscal Year | Revenue | Gross Margin | Operating Margin | Net Income | Operating Cash Flow | Capex | Free Cash Flow | Diluted Shares |
|---|---|---|---|---|---|---|---|---|
| 2021 | $6.319B | 53.9% | 21.3% | $1.210B | $1.485B | $188M | $1.297B | 307M |
| 2022 | $6.848B | 54.4% | 23.6% | $1.254B | $1.312B | $291M | $1.021B | 300M |
| 2023 | $6.833B | 50.7% | 19.8% | $1.240B | $1.772B | $298M | $1.474B | 296M |
| 2024 | $6.510B | 54.3% | 22.9% | $1.289B | $1.751B | $378M | $1.373B | 291M |
| 2025 | $6.948B | 52.4% | 21.3% | $1.303B | $1.559B | $407M | $1.152B | 285M |
In the table, the FY2021-FY2023 revenue, margins, net income, operating cash flow, and capex come from the 2023 annual report; the FY2024-FY2025 data come from the 2025 annual report; the FY2025 diluted share count comes from the EPS footnote. Free cash flow is a value calculated in this report.
How to read the financial quality. 【Fact】Over the past five years Agilent has not had the problem of "profit grows but cash flow can't keep up." As totaled from the table above, FY2021-FY2025 cumulative net income was about $6.296 billion and cumulative free cash flow was about $6.317 billion, roughly equal; cumulative operating cash flow was about $7.879 billion, clearly higher than net income. This combination usually means earnings quality is good, rather than paper profit.
【Inference】If we look at a single year, 2025 free cash flow declined versus 2024, mainly not because of a profit collapse but because of increased working-capital tie-up and higher capex. In 2025, changes in accounts receivable consumed $149 million of cash and inventory consumed $97 million; capex rose to $407 million. At the same time, the company itself explains that the 2025 increase in fixed assets was mainly related to the expansion of the Frederick, Colorado facility. In other words, 2025 cash flow was not bad, but it was indeed more "capital-hungry" than 2023-2024.
Is the balance sheet solid? At the end of FY2025, the company had cash of $1.789 billion, total assets of $12.727 billion, and total liabilities of $5.986 billion; by Q1 FY2026, cash was $1.758 billion, and long-term notes and loans totaled about $3.05 billion, plus a small amount of short-term debt. Roughly estimating EBITDA at about $1.77 billion using FY2025 EBIT plus depreciation and amortization, net debt/EBITDA is roughly below 1x; FY2025 interest expense was about $112 million, implying an EBIT interest coverage ratio of about 13x. Combined with a debt credit rating of BBB+ / Baa1, this is a fairly healthy balance sheet.
ROE, ROIC, and reinvestment capacity. 【Inference】Roughly estimating from FY2025 data, Agilent's ROE is around 20%, ROA around 10%; estimating ROIC using operating profit less a more normalized tax rate, it is most likely in the mid-teens. This is a business with decent returns. It must be emphasized that the company's book equity contains a large amount of goodwill from acquisitions, so ROE is somewhat "flattered" by the financial structure; by comparison, ROIC is more informative. On balance, I am willing to classify Agilent as a company with "excellent but not extreme returns on capital."
Accounting risk and survivability. PwC issued an unqualified opinion on both the FY2025 financial statements and internal controls. The company also did not disclose any single large customer, major liquidity shortfall, or obvious deterioration in receivables. In Q1 FY2026, management again explicitly stated that cash, operating cash flow, and access to capital markets and credit lines could meet future needs. Based on this evidence, I do not see obvious signs of financial fraud or aggressive accounting; but I would not wrongly equate "no evidence found" with "never any risk."
How to view Owner Earnings. 【Fact】FY2025 net income was $1.303 billion, depreciation and amortization $288 million, operating cash flow $1.559 billion, and capex $407 million.
【Inference】If we strictly use the most conservative approach—not guessing at "maintenance capex" but simply deducting all capex—then FY2025 Owner Earnings can be approximated at $1.152 billion, or about $4.0 per share. Considering that 2025 capex included a good deal of expansionary investment, especially the Frederick facility expansion, "normalized owner earnings" may be slightly higher than this; but to avoid self-hypnosis, I treat $1.15 billion as the conservative baseline in my valuation. At the current market cap, Agilent trades at about 28x conservative Owner Earnings, corresponding to a yield of about 3.6%. That is not a cheap-stock number.
Valuation, Margin of Safety, and Opportunity Comparison
The current market data is as follows. It is not the investment logic itself, but it helps us intuitively see "what price the market is putting on Agilent right now."
First, absolute valuation. 【Fact】The current share price is about $113.78, market cap about $32.3 billion, and the trailing-twelve-month GAAP P/E about 25.1x. The non-GAAP EPS corresponding to the midpoint of FY2026 guidance is about $5.97, implying a forward non-GAAP P/E of roughly 19x. But non-GAAP strips out M&A amortization, restructuring, and transformation costs, and cannot be directly equated with the real distributable cash available to shareholders. For a long-term business owner, I place more weight on conservative Owner Earnings and cash flow.
Discounted Owner Earnings method. The valuation below uses "starting Owner Earnings" rather than management-adjusted profit; the growth assumptions are set roughly around the company's long-term 5%-7% growth algorithm and the 4%-6% underlying growth range of its core markets. The discount rate is set at a somewhat conservative long-term required return on equity. The figures here are valuation assumptions, not facts. The factual basis supporting these assumption boundaries is the company's 2024 analyst day long-term growth framework, the Q1 FY2026 growth guidance, and the past five years of cash-flow record.
| Scenario | Starting Owner Earnings | 10-Year Growth | Discount Rate | Terminal Growth | Estimated Intrinsic Value per Share |
|---|---|---|---|---|---|
| Conservative | $1.15B | 3% | 10% | 2.5% | $55-65 |
| Fair | $1.20-1.25B | 5% | 9% | 3.0% | $80-95 |
| Optimistic | $1.25-1.30B | 7% | 8% | 3.5% | $120-135 |
My interpretation: The current price of $113.78 sits roughly at a level that is "explainable under the optimistic scenario, clearly expensive under the fair scenario, and very expensive under the conservative scenario." This pricing structure is not friendly to conservative long-term capital, because when you buy in you are already assuming many good things will happen: above-mid-single-digit organic growth, CrossLab continuing its high-quality expansion, successful M&A, resilient margins, and no significant valuation-multiple contraction.
Relative valuation method. Using only current public markets and the high-confidence peer information I have collected, we can obtain a "usable but imperfect" comparison: Agilent's current trailing P/E of about 25.1x is broadly close to Thermo Fisher's 24.8x, and below Danaher's 33.0x and Waters' 43.4x. Using free cash flow as an approximate comparison, Agilent's FY2025 P/FCF is about 28.0x; Thermo Fisher's, based on the free cash flow disclosed in its 2025 annual report, is about 26.6x; Waters', based on full-year FY2025 free cash flow, is about 43x. This shows Agilent is not absurdly expensive, but it is certainly not cheap; it looks more like "the normal or even slightly expensive valuation of a high-quality company" than a mispriced bargain. It should be noted that a complete peer table of P/B, EV/EBITDA, and ROIC, if one insists on using only the latest raw filings and real-time market caps, would still require further supplementation from peers' latest annual/quarterly filings and debt detail; to avoid false precision, I explicitly mark it here as not fully developed.
Asset or liquidation value method. This company is not suited to being priced on liquidation value. At the end of FY2025, total assets were $12.727 billion, of which goodwill was $4.473 billion and net intangible assets $445 million; the corresponding book shareholders' equity was about $6.741 billion, but tangible net assets were only about $1.8 billion. Moreover, the equipment, inventory, and specialized facilities of a laboratory-tools company are usually very difficult to recover at book value in a liquidation. Therefore, Agilent's investment logic must be "going-concern value," not "discounted asset recovery." If your investment framework leans more toward net cash, real estate, or realizable inventory, then Agilent clearly does not belong to that category.
Is there a margin of safety? My answer is: not sufficient right now. The most fragile assumption is "the market's willingness to continue paying a quality premium near that of top-tier large-cap tools stocks for this company." If future growth is below expectations, if CrossLab's advantage cannot continue to dilute the instrument cyclicality, or if M&A returns fall short, multiple compression will inflict real capital losses on holders. In the language of long-term value investing, Agilent very likely belongs to the "good company, but not a good price today" category.
Price range judgment. 【Conservative Intrinsic Value Range】$55-65. 【Fair Intrinsic Value Range】$80-95. 【Optimistic Intrinsic Value Range】$120-135. 【Ideal Buy Price Range】$70-85, corresponding to leaving roughly a 15%-30% margin of safety against "fair value." 【Acceptable Holding Price Range】$85-110, suitable for shareholders who already hold, have a low tax cost basis, and are willing to accompany the business's growth for the long term. 【Clearly Overvalued Price Range】$125 and above, unless the company clearly delivers growth and returns above my baseline in the next few years.
By this framework, $113.78 is closer to "reasonable-to-expensive" than to "safe to accumulate freely."
Comparison with other opportunities. If you simply want a "decent but not dazzling" long-term return, today's Agilent is not necessarily clearly superior to buying a broad-based index, because here you are bearing single-company execution risk, M&A integration risk, and industry-cycle risk without receiving a very significant valuation compensation. On the contrary, if the price later falls back into the ideal range I have given, only then would it qualify to compete with an index, high-quality bonds, and other high-quality compounders for "priority on capital deployment." At the current price, it looks more like a candidate worth tracking for the long term than a top-five position that must be entered today.
Risks, Checklist, and Final Judgment
The most important risks. First, competition and technological substitution risk. Agilent itself admits that industry standards change fast and competition is intense, meaning it must continuously roll out new products, new workflows, and better software/service combinations to defend its share.
Second, the "dual nature" risk of the business model. CrossLab does indeed resemble a stable installed-base business, but a considerable portion of the company's overall revenue still comes from the instrument platform, and instrument demand is affected by pharma capex, regional research funding, customer inventory adjustments, and swings in China demand. The 2023-2024 performance swings already show that this is not a "pure subscription company" fully immune to cycles.
Third, M&A and integration risk. BIOVECTRA has been integrated and the Biocare Medical deal is advancing; if integration goes poorly, if the earnings promises fall through, or if M&A intensity keeps rising to sustain growth, Agilent could slide over the next few years from "steady compounding" toward a "more aggressive capital-allocation" track. The exit and impairment of Resolution Bioscience already remind us that M&A is not without precedent for missteps.
Fourth, policy and supply-chain risk. In 2025 and Q1 2026, management explicitly mentioned that tariffs, freight, wages, and transformation costs are suppressing gross margin and operating margin. The company can absorb part of this through price increases and supply-chain adjustments, but it cannot guarantee it will be entirely painless.
Fifth, overvaluation risk. This is the risk I care about most today. A company with a conservative Owner Earnings yield of around 3.6%, even with a decent business, can easily deliver years of mediocre or even negative shareholder returns due to multiple mean reversion.
The strongest opposing view. The strongest bear case would say: Agilent is neither a more comprehensive platform giant like Thermo Fisher nor a purer player in certain high-end analytical fields like Waters; its best segment is CrossLab, but the rest remains exposed to the equipment cycle and technological competition. Yet the market gives it a valuation close to that of a high-quality large-cap tools stock. If growth in the future is merely "normal" rather than "above expectations," shareholders may still receive an unsatisfactory return because they bought expensive. I consider this bear logic to be forceful.
What facts would overturn the investment judgment? If the following facts appear, I would admit the original judgment was wrong, or at least that it needs a thorough re-evaluation: First, CrossLab's service-contract attach rate, consumables growth, and software/automation penetration slow markedly for several consecutive years, causing the non-instrument revenue share to stop rising. Second, ROIC and the free-cash-flow conversion rate weaken persistently—for example, FCF is clearly below net income for two or three consecutive years and cannot be explained by clearly high-return growth investment. Third, net leverage is pushed above 2x EBITDA by M&A, with M&A returns below the cost of capital. Fourth, the company again takes a major strategic impairment similar to Resolution, indicating a systemic problem in capital-allocation discipline. Fifth, high-growth directions such as diagnostics, pathology, and CDMO fail to raise overall quality and instead bring more volatility.
Investment Checklist.
| Check Item | Conclusion | Notes |
|---|---|---|
| Can I understand this business | Pass | Laboratory tools + services + consumables + software; the logic is clear |
| Does it have long-term stable demand | Pass | Demand from pharma, diagnostics, food, environment, compliance, etc. persists long term |
| Does it have a durable moat | Pass | But stronger in CrossLab, weaker than a pure monopoly platform |
| Does it have pricing power | Partial pass | It has targeted pricing, but competition is still intense |
| Can it generate stable free cash flow | Pass | Five-year cumulative FCF and net income broadly match |
| Are its returns on capital excellent | Pass | Normalized ROIC roughly mid-teens |
| Is management trustworthy | Partial pass | Governance is strong, but a new management combination and low insider ownership |
| Is capital allocation rational | Partial pass | Dividends and anti-dilution buybacks are steady, but M&A still needs watching |
| Is the balance sheet solid | Pass | Low net leverage, investment-grade rating |
| Is the valuation below intrinsic value | Fail | The current price is above the upper edge of my fair range |
| Is the margin of safety sufficient | Fail | Not obvious |
| Does long-term holding let me rest easy | Partial pass | The business is fine, the price is not reassuring enough |
| What key facts would make me sell | Clearly defined | See the five re-evaluation signals above |
| Am I buying only because of the stock price or emotion | Should be wary | This stock more easily tempts one to "overlook price because of quality" |
Final investment conclusion.
【Final Rating】 Watch
【One-Sentence Investment Thesis】 Agilent is a high-quality laboratory tools and services company with real cash flow and a moderately strong moat, but the current share price looks more like buying "premium certainty" than acquiring a business at a "cheap price."
【Core Bull Case】 Non-instrument revenue in the company's revenue mix already reaches $4.521 billion, and the CrossLab segment's FY2025 operating margin is as high as 32.5%, making the overall business model steadier than a traditional instrument company. Over the past five years, cumulative free cash flow and cumulative net income broadly match, showing solid earnings quality. The balance sheet is healthy and the credit rating is investment grade, giving it the ability to weather cycles and continue making small-to-mid-sized acquisitions. The company keeps doubling down on higher-stickiness areas such as pathology, CDMO, laboratory services, software, and automation, and its strategic direction is generally correct.
【Core Bear Case】 The current price does not offer a sufficient margin of safety, with a conservative Owner Earnings yield of only about 3.6%. The company's highest-quality part is CrossLab, but the whole still contains a good deal of cyclically exposed instrument business. M&A has increased over the past two years and the CFO has also changed; the quality of integration and capital allocation needs to be validated over the next two to three years. Industry competition is intense, and although the moat is good, it is not unassailable.
【Key Assumptions】 CrossLab continues to maintain high margins and high attach-rate growth; The acquired BIOVECTRA and Biocare deliver returns above the cost of capital; Overall revenue maintains mid-single-digit growth over the long term; Margins do not step down persistently under tariff, wage, and competitive pressure; Management does not use significantly higher leverage to buy external growth.
【Fair Buy Price】 $70-85. The basis is leaving a certain margin of safety against a fair intrinsic value of $80-95, rather than paying full price for a "good company."
【Target Holding Period】 More than 10 years. But the premise is a reasonable purchase valuation and continuous tracking of cash flow, CrossLab penetration, and M&A returns.
【Expected Annualized Return】 Conservative scenario: 0%-2%; Neutral scenario: 3%-6%; Optimistic scenario: 7%-10%. This is a range judgment based on the current valuation, conservative Owner Earnings yield, future growth, and possible multiple changes; it is not a price forecast.
【Maximum Downside Risk】 If future growth falls back to the low single digits, M&A returns are poor, and the market re-prices it as a more ordinary instrument company rather than a "high-quality service platform," a return to $55-75 is not unimaginable, implying a permanent-capital-loss risk range of about 35%-50% for buyers at the current price.
【Tracking Metrics】 CrossLab revenue growth and operating margin; Non-instrument revenue share; The match between free cash flow and net income; Capex intensity and the share of "growth capex"; Changes in accounts receivable and inventory; Net debt/EBITDA; Post-integration revenue synergies and margins from M&A; Performance in China, pharma, and academia/government end markets; Changes in share count and the average repurchase price; Whether management continues to disclose risks and mistakes candidly.
【Signals That Trigger Reassessment】 CrossLab growth stalls markedly; Free cash flow consistently and significantly lags net income; Net leverage rises markedly; Another large strategic impairment occurs; New high-growth businesses fail to lift overall quality; Management begins to emphasize scale over intrinsic value per share.
【Final Recommendation】 Put calmly, Agilent deserves respect, but does not deserve impulse today. If you already hold it and your cost basis is low, I lean toward holding and continuing to track; if you are waiting for a new long-term position, I would prefer to place it on a "high-quality watch list" rather than rushing to place an order at the current price. What truly suits long-term value investors is not just a good company, but a good company that meets a good price.
【Data Limitations and Unfinished Items】 To hold to "only writing what I can verify," this report has not forced together a seemingly complete but potentially distorted peer table of P/B, EV/EBITDA, and ROIC. If you want to do a fully comparable, line-by-line valuation of Agilent against Thermo Fisher, Danaher, and Waters, you would need to further extract, company by company, the cash, debt, depreciation and amortization, share count, and M&A-impact definitions from their latest annual and quarterly filings. My conclusion is therefore weighted more toward a "high-confidence absolute value judgment" than a "terminal-style, whole-market relative-valuation table."
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free